论文部分内容阅读
目的评价奥曲肽在肠梗阻治疗中的有效性及安全性。方法选取2012年1月至2013年12月收治确诊的120例肠梗阻患者,均符合非手术治疗指征,排除中重度肝肾功能障碍及有奥曲肽禁忌者,按随机数字表法分为观察组和对照组,每组各60例。对照组采用常规治疗,观察组在常规治疗的基础上加用奥曲肽静脉注射,每次0.1 mg,每日3次,连续3 d以上至症状缓解。比较两组的临床疗效及治疗的不良反应。结果观察组治愈率(80.0%vs 41.7%,P<0.05)、有效率(95.0%vs 73.3%,P<0.05)明显高于对照组。观察组腹胀缓解时间、腹痛缓解时间、肛门排气时间、胃肠减压量、住院时间均少于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论奥曲肽能有效缓解肠梗阻的临床症状,提高治愈率,且安全性好。
Objective To evaluate the efficacy and safety of octreotide in the treatment of intestinal obstruction. Methods A total of 120 patients with intestinal obstruction diagnosed from January 2012 to December 2013 were enrolled in the non-surgical indications. Patients with moderate-severe liver and kidney dysfunction and contraindications to octreotide were excluded and randomly divided into observation group And control group, 60 cases in each group. Patients in the control group were treated with conventional therapy. The observation group was given intravenous injection of octreotide 0.1 mg once daily for 3 days, and the symptoms were relieved for more than 3 days. The clinical efficacy and adverse reactions of the two groups were compared. Results The cure rate of the observation group was significantly higher than that of the control group (80.0% vs 41.7%, P <0.05), and the effective rate (95.0% vs 73.3%, P <0.05). Abdominal distension time, abdominal pain relief time, anal exhaust time, gastrointestinal decompression and hospitalization time in the observation group were all less than those in the control group, with significant difference (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Octreotide can effectively alleviate the clinical symptoms of intestinal obstruction, improve the cure rate, and good safety.